Purpose: To determine if there are differences in the timing of diagnosis and response to treatment between infants with infantile spasms (IS) and Trisomy 21 (T21) and those with idiopathic IS. Method: This was a retrospective study evaluating the time from onset of IS to diagnosis, treatment of IS, time from treatment to resolution of IS, and development of epilepsy in children with T21 and IS compared to children with idiopathic IS. Results: Thirteen children with T21 and IS were identified over a 10 year period and compared to 32 children in the control group. There was no significant difference in age of onset, time between onset and diagnosis, or acute response to treatment. However, the children with idiopathic IS were more likely to go on to develop epilepsy than those with T21 and IS (41% vs. 0, p = 0.006). Conclusion: The children with T21 and IS were diagnosed and treated similarly to those patients with idiopathic IS. There were no significant differences in the age of onset, time between the onset and diagnosis of IS, or acute treatment response of IS between the T21 and control groups. However those with T21 and IS had a lower risk of subsequent epilepsy following IS than those with idiopathic IS. IS in the T21 population appears to be inherently different from IS of unknown etiology.
Introduction
Trisomy 21 (T21), or Down syndrome, affects approximately 13 out of every 10,000 children in the United States [1] . Epilepsy is a common problem in this population and affects up to 2-13% of those with T21 [2] . Infantile spasms (IS) is also a significant manifestation of epilepsy in this cohort as 2-5% of children with T21 develop the characteristic spasms and electroencephalogram (EEG) changes [3, 4] .
The classification of IS is difficult and various diagnostic systems have been proposed. The West Delphi Group proposed a classification of "idiopathic" (unknown etiology without other neurologic signs or symptoms), "cryptogenic" (unknown etiology but suspected symptomatic), and "symptomatic" (an identifiable cause of IS is present or an unequivocal developmental delay precedes IS) [5] . Those that fall into the category of idiopathic IS have a better chance of achieving positive outcomes with resolution of IS, lower likelihood of developing epilepsy, and higher likelihood of normal cognition than those with symptomatic IS [6, 7] . Recently the International League Against Epilepsy (ILAE) has proposed a change to the categorization of these children to better reflect our understanding of the causes. Children would be categorized by the underlying etiology of their IS: structural/metabolic, genetic, or unknown etiology [8, 9] . The classification of "unknown etiology" does not differentiate between idiopathic and cryptogenic IS. This distinction is important given the differences in prognosis for these two subgroups. For this reason, the West Delphi classification will be used as it is more appropriate for the focus of the current study.
First line treatment for IS is controversial. Adrenocorticotropin hormone (ACTH), high dose prednisolone, and vigabatrin have all been used as first line therapy in various studies with data suggesting that ACTH or prednisolone are superior in those children without tuberous sclerosis [10] [11] [12] [13] [14] . Early treatment within 30 days of spasm onset has been shown to improve outcomes, with some suggestion that a delay of a week could result in worse performance on the Vineland Adaptive Behavior Scales [6, [15] [16] [17] [18] . Data in the T21 population suggests that treatment initiated within 2 months of onset of IS is associated with faster resolution of IS, improved development, and fewer autistic features [19] .
Despite appropriate therapy, there is a risk for relapse once IS has resolved. Those children with idiopathic IS have a relapse rate of 10-20% [6, 16] . The relapse rate in the T21 population was noted to be 57% in a recent study; however, the median time to treatment initiation was 3.3 months [20] .
Approximately 20% of infantile spasms are categorized as idiopathic [6, 12, 21] . While this group is thought to have a higher likelihood of favorable outcomes than symptomatic IS; there remains a risk in this population for very poor outcomes, with many developing refractory IS, epilepsy, and/or significant intellectual disability [6, 7] . In contrast, those children with T21 who develop IS appear to be very responsive to treatment with most having resolution of IS and are less likely to go on to develop epilepsy despite similar characteristics of their clinical spasms and EEGs [19, 20, 22] .
One possibility may be that the T21 population seeks care earlier in the course of the disease process, obtains earlier treatment, and thus has faster resolution of IS given that many families of children with T21 are already familiar with the medical system and may have received anticipatory guidance with regards to the possibility of IS. The purpose of this study was to determine if IS were more quickly identified in the T21 population, using time from spasm onset to diagnosis as the primary outcome. We also examined the time from treatment to clinical and EEG resolution of IS as a secondary outcome measure.
Methods
We conducted a search of ICD-9 codes for all patients treated at Seattle Children's Hospital from 1/1/2003 to 10/31/2013 for infantile spasms with or without intractability (ICD-9 345.6, 345.60, 345.61). In order to be included in the study, a child had to be diagnosed with IS at Seattle Children's Hospital after 1/1/2003. IS was defined as a clinical history of spasms and an EEG demonstrating hypsarrhythmia, modified hypsarrhythmia, or electroclinical spasms captured on EEG. The child had to initiate treatment of IS at Seattle Children's Hospital and be followed until either IS resolved or the patient reached 2 years of age. A cut off of 2 years was chosen as there is evolution of the epileptic encephalopathy and alteration of treatments after this age.
Children were then further stratified by the etiology of their IS: structural, metabolic, genetic, or unknown etiology. Genetic etiology was further subdivided to examine those children with a diagnosis of T21 (n = 18). Unknown etiology was then subdivided into idiopathic or cryptogenic IS. Children with idiopathic IS were chosen as the control group as these children have the better outcomes, thus making them a more "rigorous" comparison for T21 patients than other cohorts.
"Age of spasm onset" was determined based on parental report of onset of clinical spasms. "Age at diagnosis" was based on EEG confirmation of IS. "Clinical resolution" of spasms was determined by parental report. "EEG resolution" was defined as resolution of clinical spasms and an EEG showing resolution of hypsarrhythmia. Relapse of infantile spasms was defined as 2 weeks without reported clinical spasms followed by return of clinical infantile spasms or a return of hypsarrhythmia after resolution. This time period was chosen as the ACTH protocol used suggests treatment with ACTH for 2 weeks prior to the decision to wean, and as such is a routine time period for contact with families for management decisions.
The data were analyzed using a 
Results
We initially identified 161 children with IS who met inclusion criteria. There were 102 children who had structural, metabolic, or genetic etiologies consistent with symptomatic IS and were excluded from analysis. Eighteen children had a diagnosis of T21; however 5 of these children had other insults such as hypoxic ischemic encephalopathy or a perinatal infarct which lead to a classification as symptomatic for structural reasons as opposed to solely T21. Further analysis of these children was not completed due to associated epilepsy at the time of IS onset or goals of care that altered treatment decisions. Thirteen had T21 as the primary etiology for spasms (8% of the total IS population) and comprised our study group. Of these, 7 had neuroimaging that did not demonstrate any other underlying etiology for their infantile spasms, 6 did not undergo neuroimaging. One child with T21 did not develop hypsarrhythmia and was not included in the analyses for EEG resolution, but was included in all other analyses.
Forty-one children had no known etiology for their infantile spasms. Of these children, 9 were excluded from analysis as they had other features of an underlying disease (such as movement disorder or microcephaly) consistent with cryptogenic IS. This allowed for inclusion of 32 children into the control group, consistent with idiopathic IS. Two of these children did not have hypsarrhythmia on the EEG recording and were excluded from the analysis of EEG resolution. One of these children never had resolution of their infantile spasms and was excluded from the analysis of clinical resolution. These children were included in all other analyses.
The 32 children with idiopathic IS had varying levels of investigation. All 32 underwent neuroimaging with magnetic resonance imaging (MRI) of the brain. Investigation for metabolic disease varied, and was unremarkable for the controls: 30 (94%) plasma amino acids, 27 (84%) urine organic acids, 24 (75%) venous lactic acid, 14 (44%) pyruvate, 15 (47%) ammonia, 7 (22%) alphaaminoadipic semialdehyde, 25 (78%) acylcarnitine profile. Genetic testing was completed in some children with 10 (31%) undergoing karyotype and 9 (28%) with single nucleotide polymorphism array as part of the initial evaluation.
There was not a significant difference in the male/female distribution between the two groups (p = 0.372). The median age of onset of spasms was similar in the T21 and control groups (6.6 versus 5.6 months respectively, p = 0.12). The median time delay between clinical spasm onset and IS diagnosis was 6.9 days in the T21 cohort versus 19.5 days in those with idiopathic IS (p = 0.35) ( Table 1) .
Time from diagnosis to initiation of treatment was similar in the two cohorts. Mean duration in the control group was 1.07 days (SD 1.83) and 1.00 day (SD 1.78) in the T21 cohort (p = 0.91). This data was reported as mean duration as the median of both cohorts was zero with initiation of treatment on the day of diagnosis. Two patients had initiation of treatment with zonisamide based on clinical suspicion prior to confirmation of IS on EEG and were excluded from this analysis.
All children received treatment for IS. Treatment in our study varied based on provider preference. However, ACTH was the treatment of choice at our institution with 84.6% of the T21 group and 84.4% of the control group receiving treatment with ACTH (p = 0.98). Routinely, children were started on low dose ACTH of 75 units/m 2 per day to minimize side effects. If clinical spasms persisted after 1 week of treatment or a repeat EEG at one week demonstrated continued hypsarrhythmia, the dosage was increased to 150 units/m
2
. If the response to low dose ACTH persisted for 2 weeks, then a decision was made to wean. Otherwise, children were escalated to high dose ACTH and treated for 2 weeks prior to the decision to wean. An EEG was routinely obtained after ACTH wean to ensure resolution of hypsarrhythmia. In the T21 cohort, 6 children (54.5%) required escalation to high dose ACTH in comparison to 19 children (70.4%) in the control group (p = 0.71). Many children were initially treated with zonisamide while ACTH treatment was coordinated, MRI obtained to rule out tuberous sclerosis, and quantiferon gold testing ruled out tuberculosis. Other treatments of IS included: prednisolone, pyridoxine, vigabatrin, topiramate, the ketogenic diet, valproic acid, ganaloxone, and clonazepam.
Twelve children with T21 had both clinical and EEG resolution of their infantile spasms and one had only clinical resolution as hypsarrhythmia was not present. Two children in the control group never had hypsarrhythmia and one child in the control group never had resolution of clinical spasms. All other children in the control group had at least initial resolution of clinical spasms and hypsarrhythmia.
Time between initiation of treatment and clinical and EEG resolution was similar in the two cohorts. For the T21 cohort median duration to clinical resolution was 3.85 weeks versus 3.42 weeks in the control group (p = 0.84). With regard to EEG resolution, median duration for the T21 population was 5.87 weeks versus 5.01 weeks in the idiopathic cohort (p = 0.82).
There was no significant difference in the time from the onset of spasms to EEG or clinical resolution between the two groups (p = 0.66, p = 0.83 respectively) suggesting similar duration of disease. Median time between onset and clinical resolution was 8.57 weeks in the T21 cohort and 6.4 weeks in the control group. The median age of clinical resolution of IS was 8.3 months in the T21 cohort and 7.2 months in the control group (p = 0.23). Median age of EEG resolution was very similar for the two groups at 8.5 and 7.85 months for the T21 and control groups, respectively (p = 0.41). (Table 2) .
None of the children with T21 had a relapse of IS after resolution of clinical spasms and hypsarrhythmia, but 6 children in the control group (18.75%) had a relapse of either clinical spasms, hypsarrhythmia, or both and this difference approached significance (p = 0.094). No children in the T21 cohort went on to develop epilepsy. One child in this cohort had a single febrile seizure. In the control group, 13 children (40.6%) developed epilepsy which was a significant difference between the two groups (p = 0.031) ( Table 3) .
The children with T21 were followed in neurology clinic for a median of 9.1 months (range of 1-34 months) and those in the control group were followed for a median of 17.9 months (range of 1-118.2 months) (p = 0.03). Children with T21 were followed at our institution (in any clinic) for a median of 22.2 months (range 1.4-118.2) and the controls were followed for a median of 38.9 months (range 2.4-1119.5) which was not significant (p = 0.43). 
Discussion
There was not a significant difference in the time from onset to diagnosis in the T21 cohort in comparison to the idiopathic cohort. There was also not a significant difference in the duration from treatment to clinical or EEG resolution. This suggests that the children with T21 are not identified earlier in the course of the disease and do not respond more rapidly to treatment than children with idiopathic IS. The overall time with active spasms or hypsarrhythmia was not significantly different between the two cohorts suggesting the burden of disease was not a factor affecting outcomes.
One strength of this study was the ability to analyze the T21 cohort in comparison to the idiopathic cohort at a single treatment center using similar treatment protocols in both cohorts. Given the retrospective nature of the study and the rarity of the disease process, the sample sizes included for comparison were underpowered to detect small differences in time. While larger differences such as 2 months would have been detectable with a power of 80%, smaller differences have less power and make a type II error possible.
Despite similar time to diagnosis and response to treatment, our data suggest that the T21 population was more responsive to therapy than the idiopathic cohort due to a significant difference in the diagnosis of epilepsy after IS treatment and a suggestion of a lower rate of relapse of IS. While this was not the outcome of interest in the current study, it is worth noting given the similarity to outcomes in other studies [6, 7, 16, 21] .
The incidence of epilepsy in the T21 cohort of our study is lower than what has been reported in the literature. The reasons may be two-fold. First, children with T21 who had additional insults, such as hypoxic ischemic encephalopathy or perinatal infarcts which may have increased the risk of subsequent epilepsy were excluded from our T21 cohort. Additionally, in contrast to previous studies looking at this population, the delay between spasm onset and treatment was extremely short (approximately1-3 weeks in both cohorts). Previous studies have demonstrated that early treatment of IS leads to better outcomes in all domains which may explain the lower incidence of epilepsy in the T21 cohort [6, 16, 19] .
One limitation of the study was the variability of the work-up between the two cohorts. Not all children with T21 and IS underwent neuroimaging given that many providers did not feel this was necessary. This may have allowed the inclusion of some children with structural abnormalities. Additionally, the children identified as idiopathic underwent varied evaluations, most notably with regard to genetic testing. It is possible that some children with an underlying genetic etiology were included in the study and altered the outcome data. However, the rate of relapse and rate of developing epilepsy found in this study is similar to what has been reported in the literature for this cohort with relapse rates from 13 to 20% and subsequent epilepsy in 5-47% [6, 7, 16, 21] .
This study was not able to assess the neurodevelopmental outcome of the children. Given the altered developmental trajectory of those children with T21, it would be necessary to have structured neurodevelopmental assessment to address this issue and given the retrospective nature of this study it was not possible.
Differences in length of follow-up in neurology clinic are apparent in the two cohorts, however overall duration of follow-up at our institution was not significantly different. We suspect children with T21 were followed in neurology clinic for a shorter duration as they were less likely to go on to develop epilepsy and they were monitored by other specialists at our institution for seizure recurrence.
Overall, this study demonstrates that the time from onset to diagnosis and time from treatment to clinical and EEG response was not significantly different between the T21 cohort and children with idiopathic IS. Despite these similarities, those with T21 as the primary etiology for IS appeared to be less likely to have recurrence of spasms following treatment and were less likely to develop epilepsy after resolution of IS. This suggests that IS in the T21 population is a distinct entity and their responsiveness to ACTH in our cohort suggests this may be a treatment of choice for these children.
